{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T03:02:50Z","timestamp":1773802970336,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,4,16]],"date-time":"2018-04-16T00:00:00Z","timestamp":1523836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s11060-018-2867-8","type":"journal-article","created":{"date-parts":[[2018,4,16]],"date-time":"2018-04-16T09:29:38Z","timestamp":1523870978000},"page":"349-357","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Prognostic relevance of mutations and copy number alterations assessed with targeted next generation sequencing in IDH mutant grade II glioma"],"prefix":"10.1007","volume":"139","author":[{"given":"Maarten M. J.","family":"Wijnenga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pim J.","family":"French","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hendrikus J.","family":"Dubbink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winand N. M.","family":"Dinjens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peggy N.","family":"Atmodimedjo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan M.","family":"Kros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Fleischeuer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clemens M. F.","family":"Dirven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnaud J. P. E.","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin J.","family":"van den Bent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,4,16]]},"reference":[{"key":"2867_CR1","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803\u2013820. \n                    https:\/\/doi.org\/10.1007\/s00401-016-1545-1","journal-title":"Acta Neuropathol"},{"key":"2867_CR2","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1056\/NEJMoa1402121","volume":"372","author":"DJ Brat","year":"2015","unstructured":"Cancer Genome Atlas Research N, Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, Cooper LA, Rheinbay E, Miller CR, Vitucci M, Morozova O, Robertson AG, Noushmehr H, Laird PW, Cherniack AD, Akbani R, Huse JT, Ciriello G, Poisson LM, Barnholtz-Sloan JS, Berger MS, Brennan C, Colen RR, Colman H, Flanders AE, Giannini C, Grifford M, Iavarone A, Jain R, Joseph I, Kim J, Kasaian K, Mikkelsen T, Murray BA, O\u2019Neill BP, Pachter L, Parsons DW, Sougnez C, Sulman EP, Vandenberg SR, Van Meir EG, von Deimling A, Zhang H, Crain D, Lau K, Mallery D, Morris S, Paulauskis J, Penny R, Shelton T, Sherman M, Yena P, Black A, Bowen J, Dicostanzo K, Gastier-Foster J, Leraas KM, Lichtenberg TM, Pierson CR, Ramirez NC, Taylor C, Weaver S, Wise L, Zmuda E, Davidsen T, Demchok JA, Eley G, Ferguson ML, Hutter CM, Mills Shaw KR, Ozenberger BA, Sheth M, Sofia HJ, Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Ayala B, Baboud J, Chudamani S, Jensen MA, Liu J, Pihl T, Raman R, Wan Y, Wu Y, Ally A, Auman JT, Balasundaram M, Balu S, Baylin SB, Beroukhim R, Bootwalla MS, Bowlby R, Bristow CA, Brooks D, Butterfield Y, Carlsen R, Carter S, Chin L, Chu A, Chuah E, Cibulskis K, Clarke A, Coetzee SG, Dhalla N, Fennell T, Fisher S, Gabriel S, Getz G, Gibbs R, Guin R, Hadjipanayis A, Hayes DN, Hinoue T, Hoadley K, Holt RA, Hoyle AP, Jefferys SR, Jones S, Jones CD, Kucherlapati R, Lai PH, Lander E, Lee S, Lichtenstein L, Ma Y, Maglinte DT, Mahadeshwar HS, Marra MA, Mayo M, Meng S, Meyerson ML, Mieczkowski PA, Moore RA, Mose LE, Mungall AJ, Pantazi A, Parfenov M, Park PJ, Parker JS, Perou CM, Protopopov A, Ren X, Roach J, Sabedot TS, Schein J, Schumacher SE, Seidman JG, Seth S, Shen H, Simons JV, Sipahimalani P, Soloway MG, Song X, Sun H, Tabak B, Tam A, Tan D, Tang J, Thiessen N, Triche T Jr, Van Den Berg DJ, Veluvolu U, Waring S, Weisenberger DJ, Wilkerson MD, Wong T, Wu J, Xi L, Xu AW, Yang L, Zack TI, Zhang J, Aksoy BA, Arachchi H, Benz C, Bernard B, Carlin D, Cho J, DiCara D, Frazer S, Fuller GN, Gao J, Gehlenborg N, Haussler D, Heiman DI, Iype L, Jacobsen A, Ju Z, Katzman S, Kim H, Knijnenburg T, Kreisberg RB, Lawrence MS, Lee W, Leinonen K, Lin P, Ling S, Liu W, Liu Y, Liu Y, Lu Y, Mills G, Ng S, Noble MS, Paull E, Rao A, Reynolds S, Saksena G, Sanborn Z, Sander C, Schultz N, Senbabaoglu Y, Shen R, Shmulevich I, Sinha R, Stuart J, Sumer SO, Sun Y, Tasman N, Taylor BS, Voet D, Weinhold N, Weinstein JN, Yang D, Yoshihara K, Zheng S, Zhang W, Zou L, Abel T, Sadeghi S, Cohen ML, Eschbacher J, Hattab EM, Raghunathan A, Schniederjan MJ, Aziz D, Barnett G, Barrett W, Bigner DD, Boice L, Brewer C, Calatozzolo C, Campos B, Carlotti CG Jr, Chan TA, Cuppini L, Curley E, Cuzzubbo S, Devine K, DiMeco F, Duell R, Elder JB, Fehrenbach A, Finocchiaro G, Friedman W, Fulop J, Gardner J, Hermes B, Herold-Mende C, Jungk C, Kendler A, Lehman NL, Lipp E, Liu O, Mandt R, McGraw M, McLendon R, McPherson C, Neder L, Nguyen P, Noss A, Nunziata R, Ostrom QT, Palmer C, Perin A, Pollo B, Potapov A, Potapova O, Rathmell WK, Rotin D, Scarpace L, Schilero C, Senecal K, Shimmel K, Shurkhay V, Sifri S, Singh R, Sloan AE, Smolenski K, Staugaitis SM, Steele R, Thorne L, Tirapelli DP, Unterberg A, Vallurupalli M, Wang Y, Warnick R, Williams F, Wolinsky Y, Bell S, Rosenberg M, Stewart C, Huang F, Grimsby JL, Radenbaugh AJ, Zhang J (2015) Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 372:2481\u20132498. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1402121","journal-title":"N Engl J Med"},{"key":"2867_CR3","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1093\/neuonc\/nov182","volume":"18","author":"HJ Dubbink","year":"2016","unstructured":"Dubbink HJ, Atmodimedjo PN, Kros JM, French PJ, Sanson M, Idbaih A, Wesseling P, Enting R, Spliet W, Tijssen C, Dinjens WN, Gorlia T, van den Bent MJ (2016) Molecular classification of anaplastic oligodendroglioma using Next-Generation Sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. Neuro Oncol 18:388\u2013400. \n                    https:\/\/doi.org\/10.1093\/neuonc\/nov182","journal-title":"Neuro Oncol"},{"key":"2867_CR4","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00401-015-1409-0","volume":"129","author":"M Weller","year":"2015","unstructured":"Weller M, Weber RG, Willscher E, Riehmer V, Hentschel B, Kreuz M, Felsberg J, Beyer U, Loffler-Wirth H, Kaulich K, Steinbach JP, Hartmann C, Gramatzki D, Schramm J, Westphal M, Schackert G, Simon M, Martens T, Bostrom J, Hagel C, Sabel M, Krex D, Tonn JC, Wick W, Noell S, Schlegel U, Radlwimmer B, Pietsch T, Loeffler M, von Deimling A, Binder H, Reifenberger G (2015) Molecular classification of diffuse cerebral WHO grade II\/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol 129:679\u2013693. \n                    https:\/\/doi.org\/10.1007\/s00401-015-1409-0","journal-title":"Acta Neuropathol"},{"key":"2867_CR5","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1407279","volume":"372","author":"JE Eckel-Passow","year":"2015","unstructured":"Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, Pekmezci M, Rice T, Kosel ML, Smirnov IV, Sarkar G, Caron AA, Kollmeyer TM, Praska CE, Chada AR, Halder C, Hansen HM, McCoy LS, Bracci PM, Marshall R, Zheng S, Reis GF, Pico AR, O\u2019Neill BP, Buckner JC, Giannini C, Huse JT, Perry A, Tihan T, Berger MS, Chang SM, Prados MD, Wiemels J, Wiencke JK, Wrensch MR, Jenkins RB (2015) Glioma groups based on 1p\/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 372:2499\u20132508. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1407279","journal-title":"N Engl J Med"},{"key":"2867_CR6","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s11060-015-1948-1","volume":"125","author":"TC Ryken","year":"2015","unstructured":"Ryken TC, Parney I, Buatti J, Kalkanis SN, Olson JJ (2015) The role of radiotherapy in the management of patients with diffuse low grade glioma: a systematic review and evidence-based clinical practice guideline. J Neurooncol 125:551\u2013583. \n                    https:\/\/doi.org\/10.1007\/s11060-015-1948-1","journal-title":"J Neurooncol"},{"key":"2867_CR7","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1111\/j.1468-1331.2010.03151.x","volume":"17","author":"R Soffietti","year":"2010","unstructured":"Soffietti R, Baumert BG, Bello L, von Deimling A, Duffau H, Frenay M, Grisold W, Grant R, Graus F, Hoang-Xuan K, Klein M, Melin B, Rees J, Siegal T, Smits A, Stupp R, Wick W, European Federation of Neurological S (2010) Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force. Eur J Neurol 17:1124\u20131133. \n                    https:\/\/doi.org\/10.1111\/j.1468-1331.2010.03151.x","journal-title":"Eur J Neurol"},{"key":"2867_CR8","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1212\/CON.0000000000000537","volume":"23","author":"D Schiff","year":"2017","unstructured":"Schiff D (2017) Low-grade gliomas. Continuum 23:1564\u20131579. \n                    https:\/\/doi.org\/10.1212\/CON.0000000000000537","journal-title":"Continuum"},{"key":"2867_CR9","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1212\/WNL.0000000000002014","volume":"85","author":"A Alentorn","year":"2015","unstructured":"Alentorn A, Dehais C, Ducray F, Carpentier C, Mokhtari K, Figarella-Branger D, Chinot O, Cohen-Moyal E, Ramirez C, Loiseau H, Elouahdani-Hamdi S, Beauchesne P, Langlois O, Desenclos C, Guillamo JS, Dam-Hieu P, Ghiringhelli F, Colin P, Godard J, Parker F, Dhermain F, Carpentier AF, Frenel JS, Menei P, Bauchet L, Faillot T, Fesneau M, Fontaine D, Motuo-Fotso MJ, Vauleon E, Gaultier C, Le Guerinel C, Gueye EM, Noel G, Desse N, Durando X, Barrascout E, Wager M, Ricard D, Carpiuc I, Delattre JY, Idbaih A, Network P (2015) Allelic loss of 9p21.3 is a prognostic factor in 1p\/19q codeleted anaplastic gliomas. Neurology 85:1325\u20131331. \n                    https:\/\/doi.org\/10.1212\/WNL.0000000000002014","journal-title":"Neurology"},{"key":"2867_CR10","doi-asserted-by":"publisher","first-page":"6407","DOI":"10.1007\/s12035-015-9523-5","volume":"53","author":"T Huang","year":"2016","unstructured":"Huang T, Li S, Yang Z, Liu J, Han Y (2016) Loss of heterozygosity of 9p Is associated with poorer survival in patients with gliomas. Mol Neurobiol 53:6407\u20136412. \n                    https:\/\/doi.org\/10.1007\/s12035-015-9523-5","journal-title":"Mol Neurobiol"},{"key":"2867_CR11","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.ccell.2016.03.025","volume":"29","author":"DM Roy","year":"2016","unstructured":"Roy DM, Walsh LA, Desrichard A, Huse JT, Wu W, Gao J, Bose P, Lee W, Chan TA (2016) Integrated genomics for pinpointing survival loci within arm-level somatic copy number alterations. Cancer Cell 29:737\u2013750. \n                    https:\/\/doi.org\/10.1016\/j.ccell.2016.03.025","journal-title":"Cancer Cell"},{"key":"2867_CR12","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nox132","author":"K Aoki","year":"2017","unstructured":"Aoki K, Nakamura H, Suzuki H, Matsuo K, Kataoka K, Shimamura T, Motomura K, Ohka F, Shiina S, Yamamoto T, Nagata Y, Yoshizato T, Mizoguchi M, Abe T, Momii Y, Muragaki Y, Watanabe R, Ito I, Sanada M, Yajima H, Morita N, Takeuchi I, Miyano S, Wakabayashi T, Ogawa S, Natsume A (2017) Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. Neuro Oncol. \n                    https:\/\/doi.org\/10.1093\/neuonc\/nox132","journal-title":"Neuro Oncol"},{"key":"2867_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nox176","author":"MMJ Wijnenga","year":"2017","unstructured":"Wijnenga MMJ, French PJ, Dubbink HD, Dinjens WNM, Atmodimedjo PN, Kros JM, Smits M, Gahrmann R, Rutten GJ, Verheul JB, Fleischeuer R, Dirven CMF, Vincent AJPE, van den Bent MJ (2017) The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological and molecular analysis. Neuro Oncol. \n                    https:\/\/doi.org\/10.1093\/neuonc\/nox176","journal-title":"Neuro Oncol"},{"key":"2867_CR14","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1002\/gcc.10029","volume":"33","author":"PH Wessels","year":"2002","unstructured":"Wessels PH, Twijnstra A, Kessels AG, Krijne-Kubat B, Theunissen PH, Ummelen MI, Ramaekers FC, Hopman AH (2002) Gain of chromosome 7, as detected by in situ hybridization, strongly correlates with shorter survival in astrocytoma grade 2. Genes Chromosomes Cancer 33:279\u2013284. \n                    https:\/\/doi.org\/10.1002\/gcc.10029","journal-title":"Genes Chromosomes Cancer"},{"key":"2867_CR15","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1093\/neuonc\/now277","volume":"19","author":"MJ Bent van den","year":"2017","unstructured":"van den Bent MJ, Weller M, Wen PY, Kros JM, Aldape K, Chang S (2017) A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics. Neuro Oncol 19:614\u2013624. \n                    https:\/\/doi.org\/10.1093\/neuonc\/now277","journal-title":"Neuro Oncol"},{"key":"2867_CR16","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1093\/neuonc\/nox078","volume":"19","author":"A Aibaidula","year":"2017","unstructured":"Aibaidula A, Chan AK, Shi Z, Li Y, Zhang R, Yang R, Li KK, Chung NY, Yao Y, Zhou L, Wu J, Chen H, Ng HK (2017) Adult IDH wild-type lower-grade gliomas should be further stratified. Neuro Oncol 19:1327\u20131337. \n                    https:\/\/doi.org\/10.1093\/neuonc\/nox078","journal-title":"Neuro Oncol"},{"key":"2867_CR17","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s00401-017-1781-z","volume":"134","author":"MMJ Wijnenga","year":"2017","unstructured":"Wijnenga MMJ, Dubbink HJ, French PJ, Synhaeve NE, Dinjens WNM, Atmodimedjo PN, Kros JM, Dirven CMF, Vincent A, van den Bent MJ (2017) Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas: assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratification. Acta Neuropathol 134:957\u2013959. \n                    https:\/\/doi.org\/10.1007\/s00401-017-1781-z","journal-title":"Acta Neuropathol"},{"key":"2867_CR18","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s00401-015-1424-1","volume":"129","author":"P Wesseling","year":"2015","unstructured":"Wesseling P, van den Bent M, Perry A (2015) Oligodendroglioma: pathology, molecular mechanisms and markers. Acta Neuropathol 129:809\u2013827. \n                    https:\/\/doi.org\/10.1007\/s00401-015-1424-1","journal-title":"Acta Neuropathol"},{"key":"2867_CR19","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/modpathol.2013.165","volume":"27","author":"AK Chan","year":"2014","unstructured":"Chan AK, Pang JC, Chung NY, Li KK, Poon WS, Chan DT, Shi Z, Chen L, Zhou L, Ng HK (2014) Loss of CIC and FUBP1 expressions are potential markers of shorter time to recurrence in oligodendroglial tumors. Mod Pathol 27:332\u2013342. \n                    https:\/\/doi.org\/10.1038\/modpathol.2013.165","journal-title":"Mod Pathol"},{"key":"2867_CR20","doi-asserted-by":"publisher","first-page":"709","DOI":"10.18632\/oncotarget.588","volume":"3","author":"Y Jiao","year":"2012","unstructured":"Jiao Y, Killela PJ, Reitman ZJ, Rasheed AB, Heaphy CM, de Wilde RF, Rodriguez FJ, Rosemberg S, Oba-Shinjo SM, Nagahashi Marie SK, Bettegowda C, Agrawal N, Lipp E, Pirozzi C, Lopez G, He Y, Friedman H, Friedman AH, Riggins GJ, Holdhoff M, Burger P, McLendon R, Bigner DD, Vogelstein B, Meeker AK, Kinzler KW, Papadopoulos N, Diaz LA, Yan H (2012) Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 3:709\u2013722. \n                    https:\/\/doi.org\/10.18632\/oncotarget.588","journal-title":"Oncotarget"},{"key":"2867_CR21","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.jmoldx.2016.06.002","volume":"18","author":"HJ Dubbink","year":"2016","unstructured":"Dubbink HJ, Atmodimedjo PN, van Marion R, Krol NM, Riegman PH, Kros JM, van den Bent MJ, Dinjens WN (2016) Diagnostic detection of allelic losses and imbalances by Next-Generation Sequencing: 1p\/19q co-deletion analysis of gliomas. J Mol Diagn 18:775\u2013786. \n                    https:\/\/doi.org\/10.1016\/j.jmoldx.2016.06.002","journal-title":"J Mol Diagn"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-018-2867-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-018-2867-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-018-2867-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T23:18:53Z","timestamp":1555370333000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-018-2867-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,16]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["2867"],"URL":"https:\/\/doi.org\/10.1007\/s11060-018-2867-8","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,16]]},"assertion":[{"value":"7 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Martin J. van den Bent reports personal fees from Roche, Novartis, BMS, MSD, Actelion, Blue Earth Diagnostics, and personal fees and grants from Abbvie, all outside the submitted work. All other authors report no disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors. This study was approved by the medical ethics committee of Erasmus MC.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}